Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis

Hsing Fang Lu, Po Hsin Chou, Gan Hong Lin, Wan Hsuan Chou, Shih Tien Wang, Wirawan Adikusuma, Eko Mugiyanto, Kuo Sheng Hung, Wei Chiao Chang

研究成果: 雜誌貢獻文章同行評審

8 引文 斯高帕斯(Scopus)


Osteoporosis is characterized by decreased bone mineral density and increased risk of fracture. Raloxifene is one of the treatments of osteoporosis. However, the responses were variable among patients. Previous studies revealed that the genetic variants are involved in the regulation of treatment outcomes. To date, studies that evaluate the influence of genes across all genome on the raloxifene treatment response are still limited. In this study, a total of 41 postmenopausal osteoporosis patients under regular raloxifene treatment were included. Gene-based analysis using MAGMA was applied to investigate the genetic association with the bone mineral density response to raloxifene at the lumbar spine or femoral neck site. Results from gene-based analysis indicated several genes (GHRHR, ABHD8, and TMPRSS6) related to the responses of raloxifene. Besides, the pathways of iron ion homeostasis, osteoblast differentiation, and platelet morphogenesis were enriched which implies that these pathways might be relatively susceptible to raloxifene treatment outcome. Our study provided a novel insight into the response to raloxifene.
頁(從 - 到)8855423
期刊Disease Markers
出版狀態已發佈 - 2020

ASJC Scopus subject areas

  • 分子生物學
  • 遺傳學
  • 臨床生物化學
  • 生物化學(醫學)


深入研究「Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis」主題。共同形成了獨特的指紋。